Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, will participate in a fireside chat at the virtual Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 3:30 p.m. ET. A live webcast will be available in the Investors & Media
August 5, 2020
· 1 min read